You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Mallinckrodt
Boehringer Ingelheim
Moodys

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,541,363

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,541,363 protect, and when does it expire?

Patent 7,541,363 protects NOURIANZ and is included in one NDA.

This patent has fourteen patent family members in nine countries.

Summary for Patent: 7,541,363
Title:Microcrystal
Abstract: Microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,- 6-dione having an average particle size of less than 50 .mu.m; microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,- 6-dione having an average particle size of less than 50 .mu.m and a crystallinity of 20% or more or the like, which possess excellent solubility, stability, bioavailability, dispersing property in a pharmaceutical formulation; and the like are provided. A solid pharmaceutical formulation which is characterized by comprising the same is also provided.
Inventor(s): Kuroda; Kazutoshi (Ichikawa, JP), Aoki; Noboru (Numazu, JP), Ochiai; Toshiro (Sunto-gun, JP), Uchida; Akihiro (Sunto-gun, JP), Ishikawa; Yasuhiro (Sunto-gun, JP), Kigoshi; Makoto (Sunto-gun, JP), Hayakawa; Eiji (Sunto-gun, JP), Asanome; Kazuki (Sunto-gun, JP)
Assignee: Kyowa Hakko Kirin Co., Ltd. (Tokyo, JP)
Application Number:10/554,511
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Device;

Drugs Protected by US Patent 7,541,363

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,541,363

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-131417May 9, 2003
PCT Information
PCT FiledMay 07, 2004PCT Application Number:PCT/JP2004/006495
PCT Publication Date:November 18, 2004PCT Publication Number: WO2004/099207

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Mallinckrodt
Merck
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.